BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 17115340)

  • 1. The role of positron emission tomography in the management of recurrent colorectal cancer: a review.
    Watson AJ; Lolohea S; Robertson GM; Frizelle FA
    Dis Colon Rectum; 2007 Jan; 50(1):102-14. PubMed ID: 17115340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases.
    Wiering B; Krabbe PF; Jager GJ; Oyen WJ; Ruers TJ
    Cancer; 2005 Dec; 104(12):2658-70. PubMed ID: 16315241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET) in the management of patients with colorectal cancer.
    Pelosi E; Deandreis D
    Eur J Surg Oncol; 2007 Feb; 33(1):1-6. PubMed ID: 17126522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET/CT: will it change the way that we use CT in cancer imaging?
    Hicks RJ; Ware RE; Lau EW
    Cancer Imaging; 2006 Oct; 6(Spec No A):S52-62. PubMed ID: 17114079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of 2-fluoro-2-deoxy-D-glucose positron emission tomography in managing patients of colorectal cancer with unexplained carcinoembryonic antigen elevation at different levels.
    Liu FY; Chen JS; Changchien CR; Yeh CY; Liu SH; Ho KC; Yen TC
    Dis Colon Rectum; 2005 Oct; 48(10):1900-12. PubMed ID: 15991059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic accuracy of serial CT/magnetic resonance imaging review vs. positron emission tomography/CT in colorectal cancer patients with suspected and known recurrence.
    Potter KC; Husband JE; Houghton SL; Thomas K; Brown G
    Dis Colon Rectum; 2009 Feb; 52(2):253-9. PubMed ID: 19279420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DIAGNOSTIC ROLE OF FLUORINE-18 (18F) FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY IN DETECTING RECURRENT DISEASE IN PATIENTS WITH COLORECTAL CANCER AND ELEVATED CARCINOEMBRYONIC ANTIGEN.
    Matovina E; Mihailović J; Nikoletić K; Srbovan D
    Med Pregl; 2015; 68(11-12):376-81. PubMed ID: 26939303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colorectal cancer. Radiologic staging.
    Thoeni RF
    Radiol Clin North Am; 1997 Mar; 35(2):457-85. PubMed ID: 9087214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
    Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
    Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron emission tomography in colorectal cancer.
    Flamen P
    Best Pract Res Clin Gastroenterol; 2002 Apr; 16(2):237-51. PubMed ID: 11969236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer.
    Lonneux M; Reffad AM; Detry R; Kartheuser A; Gigot JF; Pauwels S
    Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):915-21. PubMed ID: 12111132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan.
    Shen YY; Liang JA; Chen YK; Tsai CY; Kao CH
    Hepatogastroenterology; 2006; 53(69):348-50. PubMed ID: 16795969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of recurrent colorectal cancer with positron emission tomography.
    Haji A
    Br J Hosp Med (Lond); 2007 Nov; 68(11):580-3. PubMed ID: 18087843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer.
    Valk PE; Abella-Columna E; Haseman MK; Pounds TR; Tesar RD; Myers RW; Greiss HB; Hofer GA
    Arch Surg; 1999 May; 134(5):503-11; discussion 511-3. PubMed ID: 10323422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [F-18 fluorodeoxyglucose positron emission tomography in colorectal carcinoma].
    Jörg L; Langsteger W
    Wien Med Wochenschr; 2002; 152(11-12):276-9. PubMed ID: 12138655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing the role of FDG PET-CT for potentially operable metastatic colorectal cancer.
    Culverwell AD; Chowdhury FU; Scarsbrook AF
    Abdom Imaging; 2012 Dec; 37(6):1021-31. PubMed ID: 22371087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent evidences of the use of 18F-fluorodeoxyglucose positron emission tomography in the management of colorectal cancer.
    Dias AR; Nahas SC; Camargo EE; Nahas CS
    J Surg Educ; 2007; 64(2):114-9. PubMed ID: 17462214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorodeoxyglucose whole-body positron emission tomography in colorectal cancer patients studied in routine daily practice.
    Ruhlmann J; Schomburg A; Bender H; Oehr P; Robertz-Vaupel GM; Vaupel H; Wolter H; Kozak B; Biersack HJ
    Dis Colon Rectum; 1997 Oct; 40(10):1195-204. PubMed ID: 9336115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positron emission tomography and colorectal cancer.
    Arulampalam TH; Costa DC; Loizidou M; Visvikis D; Ell PJ; Taylor I
    Br J Surg; 2001 Feb; 88(2):176-89. PubMed ID: 11167864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical impact of camera-based positron emission tomography imaging in patients with recurrent colorectal cancer.
    Miller E; Lerman H; Gutman M; Figer A; Livshitz G; Even-Sapir E
    Invest Radiol; 2004 Jan; 39(1):8-12. PubMed ID: 14701983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.